Similar articles

• No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.

  Singhal MK, Bhaskaran S, Szabo T, La Rosa R. Singhal MK, et al. Perit Dial Int. 1999 Jan-Feb;19(1):89-91. Perit Dial Int. 1999. PMID: 10201354 No abstract available.
• Atorvastatin in the management of an index patient with complete hepatic lipase deficiency.

  Hegele RA, Little JA, Connelly PW. Hegele RA, et al. Atherosclerosis. 1999 Mar;143(1):219-22. doi: 10.1016/s0021-9150(98)00266-4. Atherosclerosis. 1999. PMID: 10208500 No abstract available.
• Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.

  Atalar E, Ozmen F, Haznedaroglu I, Açil T, Ozer N, Ovünç K, Aksöyek S, Kes S. Atalar E, et al. Int J Cardiol. 2002 Aug;84(2-3):227-31. doi: 10.1016/s0167-5273(02)00148-1. Int J Cardiol. 2002. PMID: 12127376 Clinical Trial.
• Lipid-lowering medications: what the new guidelines and data mean to women.

  Schwartz JB. Schwartz JB. J Gend Specif Med. 2001;4(2):9-13. J Gend Specif Med. 2001. PMID: 11480105 Review. No abstract available.
• Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.

  Osende JI, Ruiz-Ortega M, Blanco-Colio LM, Egido J. Osende JI, et al. Nephrol Dial Transplant. 2004 Mar;19(3):528-31. doi: 10.1093/ndt/gfg538. Nephrol Dial Transplant. 2004. PMID: 14767002 Review. No abstract available.